A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study

Geoffrey R. Weiss, Stephanie Green, Edward V. Hannigan, John G. Boutselis, Earl A. Surwit, Darryl L. Wallace, David S Alberts

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.

Original languageEnglish (US)
Pages (from-to)332-336
Number of pages5
JournalGynecologic Oncology
Volume39
Issue number3
DOIs
StatePublished - 1990

Fingerprint

Carboplatin
Cervix Uteri
Squamous Cell Carcinoma
Uterine Cervical Neoplasms
Cisplatin
Poisons
Leukopenia
Thrombocytopenia
Nausea
Vomiting
Anemia
Confidence Intervals
Carcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix : A Southwest Oncology Group Study. / Weiss, Geoffrey R.; Green, Stephanie; Hannigan, Edward V.; Boutselis, John G.; Surwit, Earl A.; Wallace, Darryl L.; Alberts, David S.

In: Gynecologic Oncology, Vol. 39, No. 3, 1990, p. 332-336.

Research output: Contribution to journalArticle

Weiss, Geoffrey R. ; Green, Stephanie ; Hannigan, Edward V. ; Boutselis, John G. ; Surwit, Earl A. ; Wallace, Darryl L. ; Alberts, David S. / A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix : A Southwest Oncology Group Study. In: Gynecologic Oncology. 1990 ; Vol. 39, No. 3. pp. 332-336.
@article{f1502df98c924c668cc866b104784d3b,
title = "A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: A Southwest Oncology Group Study",
abstract = "Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15{\%} (two complete responses, four partial responses; 95{\%} confidence interval 6-29{\%}) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48{\%} of courses, anemia in 47{\%}, leukopenia in 38{\%}, and thrombocytopenia in 22{\%}. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.",
author = "Weiss, {Geoffrey R.} and Stephanie Green and Hannigan, {Edward V.} and Boutselis, {John G.} and Surwit, {Earl A.} and Wallace, {Darryl L.} and Alberts, {David S}",
year = "1990",
doi = "10.1016/0090-8258(90)90262-J",
language = "English (US)",
volume = "39",
pages = "332--336",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix

T2 - A Southwest Oncology Group Study

AU - Weiss, Geoffrey R.

AU - Green, Stephanie

AU - Hannigan, Edward V.

AU - Boutselis, John G.

AU - Surwit, Earl A.

AU - Wallace, Darryl L.

AU - Alberts, David S

PY - 1990

Y1 - 1990

N2 - Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.

AB - Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) and response durations were 2.0, 2.0, 2.5+, 2.5+, 5.25+, and 6.75 months. The major toxic effects included nausea and vomiting in 48% of courses, anemia in 47%, leukopenia in 38%, and thrombocytopenia in 22%. The activity of carboplatin against advanced cervical cancer is modest and similar to the activity of cisplatin alone. However, the toxicity profile of carboplatin is substantially better than that of cisplatin and warrants exploration of this agent against cervix cancer in more aggressive regimens or in combination with other agents.

UR - http://www.scopus.com/inward/record.url?scp=0025635642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025635642&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(90)90262-J

DO - 10.1016/0090-8258(90)90262-J

M3 - Article

C2 - 2258080

AN - SCOPUS:0025635642

VL - 39

SP - 332

EP - 336

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -